(49) used the PD-1 inhibitors natalizumab and pembrolizumab as well as the PD-L1 inhibitors atezolizumab and durvalumab for the treatment of In patients with advanced bone metastases of NSCLC, the results of the study showed that treatment with ICIs produced favorable therapeutic effects and improved prognosis in patients with advanced bone metastases of NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.